RhumbLine Advisers
SGMO

RhumbLine Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

RhumbLine Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,653
Closed -$21.4K – 4315
2024
Q2 		$21.4K Sell
59,653
-159,173
-73% -$86K ﹤0.01% 3862
2024
Q1 		$147K Buy
218,826
+3,619
+2% +$2.63K ﹤0.01% 3311
2023
Q4 		$117K Sell
215,207
-90
-0% -$41 ﹤0.01% 3402
2023
Q3 		$129K Buy
215,297
+3,159
+1% +$3.38K ﹤0.01% 3372
2023
Q2 		$276K Buy
212,138
+2,369
+1% +$3.24K ﹤0.01% 3067
2023
Q1 		$369K Buy
209,769
+15,673
+8% +$44.7K ﹤0.01% 2545
2022
Q4 		$609K Buy
194,096
+5,762
+3% +$22.4K ﹤0.01% 2371
2022
Q3 		$923K Buy
188,334
+16,601
+10% +$85.3K ﹤0.01% 2171
2022
Q2 		$711K Buy
171,733
+40,028
+30% +$173K ﹤0.01% 2316
2022
Q1 		$765K Sell
131,705
-8,249
-6% -$49K ﹤0.01% 2242
2021
Q4 		$1.05M Sell
139,954
-2,146
-2% -$18.6K ﹤0.01% 2183
2021
Q3 		$1.28M Buy
142,100
+4,285
+3% +$42.4K ﹤0.01% 2120
2021
Q2 		$1.65M Sell
137,815
-6,695
-5% -$75.8K ﹤0.01% 2032
2021
Q1 		$1.81M Sell
144,510
-12,117
-8% -$163K ﹤0.01% 1965
2020
Q4 		$2.44M Buy
156,627
+5,381
+4% +$63K ﹤0.01% 1751
2020
Q3 		$1.43M Sell
151,246
-42,504
-22% -$460K ﹤0.01% 1852
2020
Q2 		$1.74M Buy
193,750
+24,186
+14% +$224K ﹤0.01% 1810
2020
Q1 		$1.08M Buy
169,564
+5,970
+4% +$44.3K ﹤0.01% 1843
2019
Q4 		$1.37M Buy
163,594
+7,174
+5% +$66K ﹤0.01% 1950
2019
Q3 		$1.42M Buy
156,420
+5,683
+4% +$63.8K ﹤0.01% 1888
2019
Q2 		$1.62M Buy
150,737
+18,138
+14% +$193K ﹤0.01% 1856
2019
Q1 		$1.26M Sell
132,599
-2,024
-2% -$20.7K ﹤0.01% 1924
2018
Q4 		$1.54M Buy
134,623
+43,418
+48% +$539K ﹤0.01% 1803
2018
Q3 		$1.55M Sell
91,205
-6,555
-7% -$99.6K ﹤0.01% 1797
2018
Q2 		$1.39M Buy
97,760
+18,815
+24% +$313K ﹤0.01% 1866
2018
Q1 		$1.5M Sell
78,945
-87
-0.1% -$1.86K ﹤0.01% 1756
2017
Q4 		$1.3M Sell
79,032
-9,784
-11% -$146K ﹤0.01% 1836
2017
Q3 		$1.33M Buy
88,816
+6,125
+7% +$67.7K ﹤0.01% 1838
2017
Q2 		$728K Sell
82,691
-2,391
-3% -$15.3K ﹤0.01% 2121
2017
Q1 		$442K Buy
85,082
+2,549
+3% +$10.2K ﹤0.01% 2303
2016
Q4 		$252K Buy
82,533
+5,330
+7% +$19.4K ﹤0.01% 2572
2016
Q3 		$357K Sell
77,203
-570
-0.7% -$2.9K ﹤0.01% 2389
2016
Q2 		$450K Buy
77,773
+5,370
+7% +$34.2K ﹤0.01% 2255
2016
Q1 		$438K Buy
72,403
+420
+0.6% +$2.52K ﹤0.01% 2308
2015
Q4 		$657K Buy
71,983
+7,975
+12% +$61.5K ﹤0.01% 2076
2015
Q3 		$361K Sell
64,008
-3,462
-5% -$28.5K ﹤0.01% 2434
2015
Q2 		$748K Sell
67,470
-4,995
-7% -$64.4K ﹤0.01% 2066
2015
Q1 		$1.14M Buy
72,465
+10,435
+17% +$161K ﹤0.01% 1775
2014
Q4 		$943K Buy
62,030
+955
+2% +$11.6K ﹤0.01% 1854
2014
Q3 		$659K Sell
61,075
-3,875
-6% -$50.6K ﹤0.01% 2046
2014
Q2 		$992K Buy
64,950
+6,066
+10% +$87.3K ﹤0.01% 1826
2014
Q1 		$1.06M Buy
58,884
+1,710
+3% +$33K ﹤0.01% 1761
2013
Q4 		$794K Buy
57,174
+6,900
+14% +$79.4K ﹤0.01% 1967
2013
Q3 		$527K Sell
50,274
-501
-1% -$4.98K ﹤0.01% 2173
2013
Q2 		$397K Buy
+50,775
New +$443K ﹤0.01% 2433

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

RhumbLine Advisers's SGMO Position: Q3 2024 in Review

RhumbLine Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 59,653 shares — an estimated $21.4K sold.

RhumbLine Advisers first reported a position in SGMO in Q2 2013 and held it in 45 quarters. The position peaked at $2.44M in Q4 2020. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • RhumbLine Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 59,653 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $21.4K.
  • RhumbLine Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 45 quarters.
  • RhumbLine Advisers's SANGAMO THERAPEUTICS INC position peaked at $2.44M in Q4 2020.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.